Lifecore Biomedical, INC \de\ 10-Q quarterly reports

Lifecore Biomedical, Inc. reported a decrease in total revenues and a widening net loss for the second quarter of 2026, impacted by a significant decline in CDMO services.

Lifecore Biomedical reported a significant decrease in total revenues for the first quarter of 2026, driven by lower demand in HA manufacturing and CDMO services.

Lifecore Biomedical, a CDMO and HA manufacturer, reported a 26% increase in total revenues to $31.1 million for the quarter ended September 30, 2025, alongside a reduced net loss.

Lifecore Biomedical's Q3 2025 results reveal a slight revenue decrease and a significant net loss increase, impacted by restructuring, legal expenses, and the loss on the sale of assets.

Lifecore Biomedical's second quarter results show revenue growth offset by increased operating expenses and a net loss, while the company navigates ongoing restructuring and legal issues.

Lifecore Biomedical's first quarter results show a net loss of $16.23 million, impacted by restructuring costs and increased professional fees, despite a rise in gross profit.

Lifecore Biomedical's Q3 2024 results show revenue growth driven by fermentation and CDMO segments, but the company continues to navigate financial and operational challenges.

Lifecore Biomedical saw a significant increase in revenue in the second quarter of 2024, but this was offset by restructuring costs and changes in the fair value of debt derivative liabilities.

Lifecore Biomedical's first quarter of fiscal year 2024 saw a revenue increase driven by CDMO growth, but was impacted by lower gross profit margins and a net loss.